The proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa was examined by introducing the cloned wild-type Escherichia coli gyrA and gyrB genes. Of 101 spontaneous mutants of P. aeruginosa PA0505, 33 (33%) were found to have gyrA mutations. Among 17 clinical isolates, 12 (71%) had gyrA mutations and 1 (6%) had a gyrB mutation.
Quinolone-resistant organisms are increasing as quinolone derivatives are used clinically for various kinds of infections. Quinolone resistance is caused by chromosomal mutations affecting permeability (1, 2, 6-9, 15, 16, 18) or drug susceptibility of DNA gyrase (EC 5.99.1.3) (3-7, 10, 14-20) . In Escherichia coli, it has been revealed by transformation with cloned wild-type gyrA and gyrB genes that mutations in the gyrA and gyrB genes are equally frequent in spontaneous quinolone-resistant mutants, whereas mutations in the former gene predominate in quinolone-resistant clinical isolates (14) . In Pseudomonas aeruginosa, what kind(s) of mutation predominates is not yet known. Since we found that the cloned wild-type E. coli gyrA gene could make a quinolone-resistant nalA mutant of P. aeruginosa quinolone susceptible just as with a quinolone-resistant gyrA mutant of E. coli, the proportion of gyr mutations in quinolone-resistant P. aeruginosa was examined by transformation with cloned E. coli gyrA and gyrB genes.
P. aeruginosa PA0505 (15) , its naLA mutant PAO51S (15) , and its transport mutant, PA06002 (nalB) (15) and plasmid pME294, which multiplies in P. aeruginosa and was constructed by Y. Itoh (11) , were used. They were kindly supplied by S. Iyobe. Spontaneous quinolone-resistant mutants of P. aeruginosa PAO505 were isolated at mutation frequencies of about 10-9 on LB agar (13) containing nalidixic acid at 8 or 16 times the MIC (400 or 800 ,ug/ml, respectively) or enoxacin at 8 or 12 times the MIC (6.25 or 9.4 ,ug/ml, respectively). Quinolone-resistant clinical isolates were obtained from patients with urinary or respiratory tract infections. Plasmid pPAW207 carrying the wild-type E. coli gyrA gene was constructed by inserting a 4.5-kilobase filledin StuI-Spll fragment containing the gyrA gene from pAW011 (20) into the SmaI site of pME294 (11 tible strains and at 3,200 ,ug/ml for carbenicillin-resistant strains.
The nalA mutant PAO51S was 16-fold or more resistant than its parent, PAOS05, to nalidixic acid and enoxacin (Table 1) . When it was transformed with pPAW207, carbenicillin-resistant transformants appeared at the same frequency as when it was transformed with pME294, and all of the transformants checked were fully quinolone susceptible without segregation, indicating that the wild-type E. coli gyrA gene carried on pPAW207 complemented the mutant P. aeruginosa nalA gene on the chromosome without recombination and conferred quinolone susceptibility on the cells. This phenomenon was not due to gene dosage effect because the parent strain, PAO505, remained quinolone susceptible when it was transformed with a similar plasmid with the quinolone-resistant E. coli gyrA allele (data not shown). This result also shows that the recombination between E. coli and P. aeruginosa gyrA genes does not cause quinolone resistance under the experitnental conditions employed, although PAOOS5 is not genotypically recombination deficient. These results show that the nalA gene of PAO51S corresponds to the gyrA gene and that the wild-type E. coli gyrA gene is dominant over the quinolone-resistant gyrA gene in P. aeruginosa. When PAOS1S was transformed with pPBW801, it remained quinolone resistant. It was interesting that susceptibility of the pPAW207 transformant to quinolones was similar to that of PAO505 (MICs of nalidixic acid and enoxacin: 50 and 0.78 ,ug/ml, respectively) and distinct from that of E. coli KL16 (MICs of nalidixic acid and enoxacin: 3.13 and 0.1 pug/ml, respectively) from which the wild-type gyrA gene was derived.
Spontaneous quinolone-resistant mutants were isolated from PAOOS5 by nalidixic acid or enoxacin selection. These 34, 1990 strains that were concurrently resistant to antibiotics remained resistant to these antibiotics after transformation with pPAW207 or pPBW801 (data not shown). The other four clinical isolates (24%) remained unidentified with respect to gyr mutations because their carbenicillin resistance was so high that it prevented transformation.
